drugset / Trial / NCT01301040

Early Cardiac Toxicity of Adjuvant CT in Elderly BC.

NCT01301040 ↗

Phase 2 Terminated 2 enrolled Jules Bordet Institute Sanofi · collab
RandomizedParallel-groupOpen-labelDiagnostic

Summary

The primary objective is to evaluate the difference in cardiac strain rate evolution in elderly early BC patients treated with (neo) adjuvant anthracycline-based chemotherapy compared with a non-anthracycline regimen (Taxotere-cyclophosphamide) CT. This study also will compare the serum biomarkers profile during and after the (neo) adjuvant CT in both treatment arms, assess whether MRI allows detecting earlier than standard echocardiography the signs of cardiotoxicity, during and after adjuvant (neo) CT, assess whether brain PET-CT allows detecting regional functional impairment in patients receiving CT, evaluate cognitive function before and after (neo) adjuvant CT in both treatment arms, evaluate distress and functional autonomy before and after (neo) adjuvant CT in both treatment arms, evaluate psychological state and burden of primary caregivers before and after (neo) adjuvant CT in both treatment arms, evaluate primary caregivers abilities to detect patients' distress and functional autonomy before and after (neo) adjuvant CT in both treatment arms, evaluate the short and long-term toxicity profile of the regimens, estimate the 10-year risk of relapse and/or death using the Adjuvant!Online tool, and estimate the Framingham risk score for Hard Coronary Heart Disease (10-year risk).

Timeline

Start
2011-03
Primary completion
2013-03
Completion
2016-03

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Comparator Docetaxel Small molecule 75 mg/m2 Intravenous
Comparator Epirubicin Small molecule 100 mg/m2 Intravenous

Indications